Yanagihara Katsunori, Kadota Junichi, Aoki Nobuki, Matsumoto Tetsuya, Yoshida Masaki, Yagisawa Morimasa, Oguri Toyoko, Sato Junko, Ogasawara Kazuhiko, Wakamura Tomotaro, Sunakawa Keisuke, Watanabe Akira, Iwata Satoshi, Kaku Mitsuo, Hanaki Hideaki, Ohsaki Yoshinobu, Watari Tomohisa, Toyoshima Eri, Takeuchi Kenichi, Shiokoshi Mayumi, Takeda Hiroaki, Miki Makoto, Kumagai Toshio, Nakanowatari Susumu, Takahashi Hiroshi, Utagawa Mutsuko, Nishiya Hajime, Kawakami Sayoko, Kobayashi Nobuyuki, Takasaki Jin, Mezaki Kazuhisa, Konosaki Hisami, Aoki Yasuko, Yamamoto Yumiko, Shoji Michi, Goto Hajime, Saraya Takeshi, Kurai Daisuke, Okazaki Mitsuhiro, Niki Yoshihito, Yoshida Koichiro, Kawana Akihiko, Saionji Katsu, Fujikura Yuji, Miyazawa Naoki, Kudo Makoto, Sato Yoshimi, Yamamoto Masaki, Yoshida Takashi, Nakamura Masahiko, Tsukada Hiroki, Imai Yumiko, Tsukada Ayami, Kawasaki Satoshi, Honma Yasuo, Yamamoto Toshinobu, Ban Nobuyoshi, Mikamo Hiroshige, Sawamura Haruki, Miyara Takayuki, Toda Hirofumi, Sato Kaori, Nakamura Tadahiro, Fujikawa Yasunori, Mitsuno Noriko, Mikasa Keiichi, Kasahara Kei, Sano Reiko, Sugimoto Keisuke, Asari Seishi, Nishi Isao, Toyokawa Masahiro, Miyashita Naoyuki, Koguchi Yutaka, Kusano Nobuchika, Mihara Eiichirou, Kuwabara Masao, Watanabe Yaeko, Kawasaki Yuji, Takeda Kenichi, Tokuyasu Hirokazu, Masui Kayoko, Negayama Kiyoshi, Hiramatsu Kazufumi, Aoki Yosuke, Fukuoka Mami, Magarifuchi Hiroki, Nagasawa Zenzo, Suga Moritaka, Muranaka Hiroyuki, Morinaga Yoshitomo, Honda Junichi, Fujita Masaki
The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Nagasaki University School of Medicine, Nagasaki, Japan.
The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Oita University Faculty of Medicine, Oita, Japan.
J Infect Chemother. 2015 Jun;21(6):410-20. doi: 10.1016/j.jiac.2015.02.008. Epub 2015 Feb 28.
The nationwide surveillance on antimicrobial susceptibility of bacterial respiratory pathogens from patients in Japan, was conducted by Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases and Japanese Society for Clinical Microbiology in 2010. The isolates were collected from clinical specimens obtained from well-diagnosed adult patients with respiratory tract infections during the period from January and April 2010 by three societies. Antimicrobial susceptibility testing was conducted at the central reference laboratory according to the method recommended by Clinical and Laboratory Standard Institutes using maximum 45 antibacterial agents. Susceptibility testing was evaluable with 954 strains (206 Staphylococcus aureus, 189 Streptococcus pneumoniae, 4 Streptococcus pyogenes, 182 Haemophilus influenzae, 74 Moraxella catarrhalis, 139 Klebsiella pneumoniae and 160 Pseudomonas aeruginosa). Ratio of methicillin-resistant S. aureus was as high as 50.5%, and those of penicillin-intermediate and -resistant S. pneumoniae were 1.1% and 0.0%, respectively. Among H. influenzae, 17.6% of them were found to be β-lactamase-non-producing ampicillin (ABPC)-intermediately resistant, 33.5% to be β-lactamase-non-producing ABPC-resistant and 11.0% to be β-lactamase-producing ABPC-resistant strains. Extended spectrum β-lactamase-producing K. pneumoniae and multi-drug resistant P. aeruginosa with metallo β-lactamase were 2.9% and 0.6%, respectively. Continuous national surveillance of antimicrobial susceptibility of respiratory pathogens is crucial in order to monitor changing patterns of susceptibility and to be able to update treatment recommendations on a regular basis.
2010年，日本化疗学会、日本传染病协会和日本临床微生物学会对日本患者的细菌性呼吸道病原体进行了全国范围的抗菌药物敏感性监测。这些分离株是由这三个学会在2010年1月至4月期间，从确诊为呼吸道感染的成年患者的临床标本中收集的。抗菌药物敏感性试验在中央参考实验室按照临床和实验室标准协会推荐的方法进行，最多使用45种抗菌药物。对954株菌株（206株金黄色葡萄球菌、189株肺炎链球菌、4株化脓性链球菌、182株流感嗜血杆菌、74株卡他莫拉菌、139株肺炎克雷伯菌和160株铜绿假单胞菌）进行了敏感性试验评估。耐甲氧西林金黄色葡萄球菌的比例高达50.5%，青霉素中介和耐药肺炎链球菌的比例分别为1.1%和0.0%。在流感嗜血杆菌中，发现17.6%为不产β-内酰胺酶的氨苄西林（ABPC）中介耐药，33.5%为不产β-内酰胺酶的ABPC耐药，11.0%为产β-内酰胺酶的ABPC耐药菌株。产超广谱β-内酰胺酶的肺炎克雷伯菌和产金属β-内酰胺酶的多重耐药铜绿假单胞菌分别为2.9%和0.6%。持续开展全国范围内呼吸道病原体抗菌药物敏感性监测对于监测敏感性变化模式以及定期更新治疗建议至关重要。
